INVITRO INTRINSIC RADIATION SENSITIVITY OF GLIOBLASTOMA-MULTIFORME

被引:95
|
作者
TAGHIAN, A
SUIT, H
PARDO, F
GIOIOSO, D
TOMKINSON, K
DUBOIS, W
GERWECK, L
机构
[1] Edwin L. Steele Laboratory of Radiation Biology, Department of Radiation Oncology, Massachusetts General Hospital, Boston
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1992年 / 23卷 / 01期
关键词
INTRINSIC RADIOSENSITIVITY; SF2; MALIGNANT GLIOMA;
D O I
10.1016/0360-3016(92)90543-Q
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Glioblastoma multiforme is one of the most resistant of human tumors to radiation whether used alone or in combination with surgery and/or chemotherapy. This resistance may be caused by one or more of several different factors. These include inherent cellular radiation sensitivity, an efficient repair of radiation damage, an increased number of clonogens per unit of volume, a high hypoxic fraction, high [GSH] concentration, and rapid proliferation between fractions. In the present study, we evaluate the intrinsic radiation sensitivity (surviving fraction at 2 Gy or mean inactivation dose) of malignant human glioma cells in vitro. The in vitro radiation sensitivity of 21 malignant glioma cell lines (early and long term passages) has been measured using colony formation as the end-point of cell viability. The survival curve parameters (SF2 measured and calculated, alpha, beta, D0, n approximately, and MID) have been determined for single dose irradiations of exponential phase cells (18-24 hr after plating) under aerobic conditions and growing on plastic. The mean SF2 of the 21 cell lines is 0.51 +/- 0.14 (with a range of 0.19 to 0.76). This value may be compared to the mean SF2 of 0.43-0.47 for SCC, 0.43 for melanoma, and 0.52 for glioblastoma as reported from other authors when using colony formation of cells in exponential phase on plastic. Although glioblastoma is almost invariably fatal, our data demonstrate a very wide range of intrinsic radiosensitivities. These broadly overlap the radiation sensitivities of cell lines from tumors that are often treated successfully. We conclude that standard in vitro measurements of cellular radiation sensitivity (SF2) do not yield values that track in a simple manner with local control probability at the clinical level and that, for at least some of the tumors, other parameters and/or physiological factors are more important.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 50 条
  • [31] Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme
    Jastaniyah, Noha
    Murtha, Albert
    Pervez, Nadeem
    Le, Duc
    Roa, Wilson
    Patel, Samir
    Mackenzie, Marc
    Fulton, Dorcas
    Field, Colin
    Ghosh, Sunita
    Fallone, Gino
    Abdulkarim, Bassam
    RADIATION ONCOLOGY, 2013, 8
  • [32] Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme
    Fadul, Camilo E.
    Fisher, Jan L.
    Gui, Jiang
    Hampton, Thomas H.
    Cote, Anik L.
    Ernstoff, Marc S.
    NEURO-ONCOLOGY, 2011, 13 (04) : 393 - 400
  • [33] ADDITION OF BEVACIZUMAB TO STANDARD RADIATION THERAPY AND DAILY TEMOZOLOMIDE IS ASSOCIATED WITH MINIMAL TOXICITY IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
    Vredenburgh, James J.
    Desjardins, Annick
    Kirkpatrick, John P.
    Reardon, David A.
    Peters, Katherine B.
    Herndon, James E., II
    Marcello, Jennifer
    Bailey, Leighann
    Threatt, Stevie
    Sampson, John
    Friedman, Allan
    Friedman, Henry S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (01): : 58 - 66
  • [34] Advances in drug delivery technology for the treatment of glioblastoma multiforme
    Cha, Gi Doo
    Kang, Taegyu
    Baik, Seungmin
    Kim, Dokyoon
    Choi, Seung Hong
    Hyeon, Taeghwan
    Kim, Dae-Hyeong
    JOURNAL OF CONTROLLED RELEASE, 2020, 328 : 350 - 367
  • [35] The hidden architects of glioblastoma multiforme: Glioma stem cells
    Sahoo, Om S.
    Mitra, Rhiti
    Nagaiah, Naveen K. H.
    MEDCOMM-ONCOLOGY, 2024, 3 (01):
  • [36] Protein patterns and proteins that identify subtypes of glioblastoma multiforme
    Makoto Furuta
    Robert J Weil
    Alexander O Vortmeyer
    Steve Huang
    Jingqi Lei
    Tai-Nan Huang
    Youn-Soo Lee
    Deb A Bhowmick
    Irina A Lubensky
    Edward H Oldfield
    Zhengping Zhuang
    Oncogene, 2004, 23 : 6806 - 6814
  • [37] Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme
    Nieder, C
    Nestle, U
    Ketter, R
    Kolles, H
    Gentner, SJ
    Steudel, WI
    Schnabel, K
    RADIATION ONCOLOGY INVESTIGATIONS, 1999, 7 (01): : 36 - 41
  • [38] Glioblastoma Multiforme-A Look at the Past and a Glance at the Future
    King, Jasmine L.
    Benhabbour, Soumya Rahima
    PHARMACEUTICS, 2021, 13 (07)
  • [39] Protein patterns and proteins that identify subtypes of glioblastoma multiforme
    Furuta, M
    Weil, RJ
    Vortmeyer, AO
    Huang, S
    Lei, JQ
    Huang, TN
    Lee, YS
    Bhowmick, DA
    Lubensky, IA
    Oldfield, EH
    Zhuang, ZP
    ONCOGENE, 2004, 23 (40) : 6806 - 6814
  • [40] Gene therapy in glioblastoma multiforme: Can it be a role changer?
    Rayati, Mohammad
    Mansouri, Vahid
    Ahmadbeigi, Naser
    HELIYON, 2024, 10 (05)